// App-Quantinova.ai

OP0164 : BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS

Researchers

Presenter

  • R. Furie

Principal Investigators

  • B. H. Rovin

  • F. Houssiau

  • Z. Amoura

  • M. Santiago

  • G. Contreras

  • A. Malvar

  • C. C. Mok

  • A. Saxena

  • X. Yu

  • Y. K. O. Teng

  • C. Barnett

  • S. Burriss

  • Y. Green

  • B. Ji

  • C. Kleoudis

  • D. Roth

Medical Centers

  • Northwell Health, Great Neck, United States

  • The Ohio State University, Columbus, United States of America

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Sorbonne Universites, Paris, France

  • Groupe Hospitalier Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris, Paris, France

  • Escola Bahiana de Medicina e Saude Publica, Salvador, Bahia, Brazil

  • University of Miami Miller School of Medicine, Miami, Florida, United States

  • Organizacion Medica de Investigacion, Buenos Aires, Argentina

  • Tuen Mun Hospital, Hong Kong SAR, China

  • NYU School of Medicine, New York City, United States of America

  • Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

  • Leiden University Medical Centre, Leiden, Netherlands

  • GlaxoSmithKline, Uxbridge, United Kingdom

  • GlaxoSmithKline plc, Collegeville, United States of America

  • Parexel, Durham, United States of America

Locations

  • United States

  • Belgium

  • France

  • Brazil

  • Argentina

  • China

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Autoimmune (AI)

Disease

  • Lupus nephritis

  • Renal disease

  • Nephritis

  • Lupus

  • End stage renal disease

Biomarkers

  • Creatinine

Drug/Treatment

  • Belimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT01639339

Sponsors

  • GlaxoSmithKline (GSK)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved